Plain-English translation of NCT07552467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Researchers are testing a new type of imaging scan called LRRC15-targeted PET imaging, which uses a special radioactive tracer to help detect and stage several types of cancer, including pancreatic, breast, lung, and colorectal cancers. The scan combines the radioactive tracer with either a PET/MR or PET/CT machine to create detailed pictures of tumors. The goal is to see if this new imaging method can accurately identify cancers and help doctors make better treatment decisions.
Currently, doctors use standard imaging scans to find and stage cancers, but these methods don't always clearly show all tumors or distinguish cancer from other tissue. This trial aims to develop a more precise imaging tool that specifically targets cancer cells, which could help doctors detect tumors earlier and plan treatments more accurately.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive an injection of the new radioactive tracer and then undergo imaging scans using either a PET/MR or PET/CT machine to create detailed pictures of your body. For patients with cancer, your imaging results will be compared with standard imaging methods and, if available, with biopsy results to evaluate how well the new tracer works. Healthy volunteers will also undergo these scans to help researchers understand how the tracer moves through the body and to confirm it is safe. The study involves approximately 26 total participants and will include follow-up visits as specified by the research team.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China